Printer Friendly
The Free Library
14,503,743 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Synthetic drug slows glaucoma in rats.


In glaucoma, pressure buildup in the eyeball can lead to blindness by disabling the nerves in the back of the eye that send images to the brain. The pressure causes excessive production of nitric oxide nitric oxide or nitrogen monoxide, a colorless gas formed by the combustion of nitrogen and oxygen as given by the reaction: energy + N2 + O2 → 2NO; m.p. −163.6°C;; b.p. −151.8°C;. , which can assume a toxic form that kills the retinal cells that carry information through the optic nerve optic nerve: see vision. .

By neutralizing an enzyme known to spur nitric oxide production, researchers studying rats at Washington University in St. Louis “Washington University” redirects here. For other uses, see Washington (disambiguation).
Washington University in St. Louis is a private, coeducational, research university located in St. Louis, Missouri.
 are now able to hold such nerve damage at bay---even if pressure in the eye remains high.

Eye pressure rises when normal fluid discharge from the eye becomes blocked. Pressure-reducing medication such as beta-blockers can ease this condition in many glaucoma patients, but some forms of the disease resist these drugs and continue to destroy nerve cells, which don't regenerate.

The scientists cauterized blood vessels Blood vessels

Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names.
 to induce high pressure in one eye of each of 16 rats. Half the rats then received aminoguanidine in their drinking water. This synthetic drug inactivates nitric oxide synthase-2, or NOS-2, an enzyme that responds to the tissue damage by launching--for reasons that are still unknown--a flurry of nitric oxide production.

Over 6 months, nerve cells called ganglion cells remained constant in each rat's healthy eye. The unmedicated rats, however, lost an average of 36 percent of the ganglion cells in the retinas of the eyes with glaucoma. Those getting aminoguanidine did not lose significant numbers of these cells, says study coauthor Arthur H. Neufeld, an ophthalmic pharmacologist.

Abnormally high pressure persisted in the cauterized eyes of both groups of rats. "We showed that despite the pressure, we were still able to protect the ocular ganglion cells," says Neufeld. The findings appear in the Aug. 17 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES The Proceedings of the National Academy of Sciences of the United States of America, usually referred to as PNAS, is the official journal of the United States National Academy of Sciences. .

Monthly examinations of the rats revealed cupping of the optic disk at the back of the untreated eyes with glaucoma. Such malformation malformation /mal·for·ma·tion/ (-for-ma´shun)
1. a type of anomaly.

2. a morphologic defect of an organ or larger region of the body, resulting from an intrinsically abnormal developmental process.
 serves as a sign of glaucoma in people.

Since a rat's life span is only a few years, the 6 months needed for significant nerve damage to accumulate parallels the period of years over which the common chronic form of glaucoma develops in people, Neufeld says.

In this study, the scientists were able "to find a way to really protect the optic nerve, not just lower eye pressure," says Paul L. Kaufman, an ophthalmologist ophthalmologist /oph·thal·mol·o·gist/ (of?thal-mol´ah-jist) a physician who specializes in ophthalmology.

oph·thal·mol·o·gist
n.
A physician who specializes in ophthalmology.
 at the University of Wisconsin-Madison “University of Wisconsin” redirects here. For other uses, see University of Wisconsin (disambiguation).
A public, land-grant institution, UW-Madison offers a wide spectrum of liberal arts studies, professional programs, and student activities.
. Because this study opens the door to treatments aimed at inhibiting the NOS-2 enzyme, "it will likely be considered a classic in years to come," he says.

Excess nitric oxide begets a toxic substance called peroxynitrite. Neufeld hypothesizes that curbing nitric oxide production limits peroxynitrite concentrations. The compound is thought to degrade nerve cells and possibly induce apoptosis, or programmed cell death pro·grammed cell death
n.
See apoptosis.



programmed cell death

proposed system of cell death, often including poly(ADP)-ribosylation, ensures that a cell will not survive if it is so badly damaged that its recovery would harm the
.

Whatever the precise mechanism behind the nerve damage, the study shows that aminoguanidine protects against it in the rat model, Neufeld says. Aminoguanidine was originally developed and tested, without much success, as a treatment for diabetes. Its prospects as a glaucoma drug seem brighter.

While lowering eye pressure eases glaucoma in many cases, too much pressure reduction can do damage. As a result, the enzyme-blocking approach for glaucoma "is very much welcomed," says Carl Kupfer, director of the National Eye Institute in Bethesda, Md.
COPYRIGHT 1999 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Author:Seppa, N.
Publication:Science News
Article Type:Brief Article
Geographic Code:1USA
Date:Aug 21, 1999
Words:537
Previous Article:Schizophrenia caregivers take health hit.(Brief Article)
Next Article:Travelin' Light.(possible use of solar sails on spacecraft)
Topics:



Related Articles
Delivering the goods; designing a new drug is one thing; getting it to the disease is another.
Eyeing the optic nerve: laser finds early signs of blinding glaucoma. (includes information on glaucoma's roots and risks )
Blacks' high glaucoma risk is verified.
Light at the end of the tunnel: visionary research probes the genesis of glaucoma. (genetic research) (Cover Story)
Breathing freely threatens seeing clearly. (inhaled steroids linked to glaucoma risk)(Brief Article)
Old drug, new uses? Anemia drug also protects against nerve damage.(erythopoietin)
Synthetic molecule may treat anemia. (Chemistry).(erythropoietin)(Brief Article)
When protein breakdown breaks down: bacterial toxin yields signs of Parkinson's.(This Week)
Me and my metabolism: personalized medicine takes new direction.(This Week)
Total recall: drug shows long-lasting boosts of memory in rats.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles